Individualising Tyrosine Kinase Inhibitor Therapy in CML to Facilitate Successful Treatment Free Remission [ 2014 - 2017 ]

Also known as: Individualising CML Therapy to Facilitate Successful Treatment Free Remission

Research Grant

[Cite as]

Researchers: Dr Craig Wallington-Beddoe (Principal investigator)

Brief description This project will determine the optimal therapy for patients with chronic myeloid leukaemia (CML), matching the most appropriate drug to the individual patient, based on each patient's unique biology, thereby maximising the chance of cure. Furthermore, this project will develop novel highly sensitive tests for the presence of residual disease, even if undetectable by current techniques. This will enable crucial, timely treatment changes to be made with curative intent.

Funding Amount $AUD 376,449.66

Funding Scheme Early Career Fellowships

Notes Peter Doherty Biomedical ECF

Viewed: [[ro.stat.viewed]]